Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA/CMS Device Trade Secret Memo Added To Regulatory Reform Wish List

This article was originally published in The Gray Sheet

Executive Summary

FDA and CMS should issue a memorandum of understanding on maintaining confidentiality and trade secrets during collaborations between the agencies in evaluating new devices, according to the HHS Secretary's Advisory Committee on Regulatory Reform

You may also be interested in...



QS Initiative Gains Significance In 2003 Budget Crunch – McClellan

FDA's quality systems improvement initiative is the vehicle by which Commissioner Mark McClellan hopes to leverage substantial device review reforms from CDRH's FY 2003 appropriation of $208 mil

QS Initiative Gains Significance In 2003 Budget Crunch – McClellan

FDA's quality systems improvement initiative is the vehicle by which Commissioner Mark McClellan hopes to leverage substantial device review reforms from CDRH's FY 2003 appropriation of $208 mil

BioLuminate Breast Cancer Detector R&D Delayed By Financing Drought

BioLuminate will launch a 12-center, 1,000-patient Phase III pivotal trial to support a PMA application for its Smart Probe breast cancer detection tool as an adjunct to mammography, following completion of a 150-patient Phase I/II study later this year

Related Content

UsernamePublicRestriction

Register

MT017141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel